Dong-A ST Achieves Milestone with FDA Approval
Dong-A ST has exciting news as it proudly announces the U.S. Food and Drug Administration (FDA) approval of its biosimilar, Imuldosa™ (ustekinumab-srlf). This significant achievement marks a pivotal moment in Dong-A ST's quest to provide effective treatments for autoimmune diseases.
The Impact and Significance of Imuldosa™
Imuldosa™, which references the renowned medication Stelara® developed by Janssen Biotech Inc., is the company’s second FDA-approved biosimilar. This milestone follows the launch of Sivextro® (tedizolid phosphate) back in 2014, a testament to Dong-A ST's commitment to research and development. With its approval, Dong-A ST demonstrates its capability to contribute meaningfully to the biopharmaceutical landscape.
Understanding the Role of Biosimilars
Biosimilars like Imuldosa are essential for providing patients access to vital treatments at a potentially lower cost. Stelara® is widely recognized for treating several serious autoimmune conditions, including plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. As a blockbuster drug, it has generated impressive global sales of approximately US$10.86 billion as of 2023, evidencing the enormous demand for effective treatments in this area.
Collaboration and Development Journey
The journey for Imuldosa began in 2013 when Dong-A Socio Holdings partnered with Meiji Seika Pharma. In July 2020, the rights for further research and commercialization transferred to Dong-A ST to streamline the project. This effective management strategy has positioned Dong-A ST favorably in the competitive market of biosimilars.
Global Strategy for Commercialization
As part of its ambitious global strategy, Dong-A ST entered into a licensing agreement with Intas Pharmaceuticals, allowing them to commercialize Imuldosa through its subsidiaries, including Accord BioPharma in the U.S. and Accord Healthcare in the EU, UK, and Canada. This collaboration not only boosts the biosimilar's market potential but also signifies confidence within the industry regarding its viability and accessibility.
Future Prospects and Commitment to Innovation
Dr. Jae-Hong Park, the Head of R&D at Dong-A ST, expressed enthusiasm regarding the FDA approval stating, “This FDA approval indicates global recognition of Dong-A ST’s R&D excellence and global competitiveness.” He emphasized the company’s commitment to launching Imuldosa in the U.S., aiming to strengthen their position as an innovator in the pharmaceutical industry. With plans well underway for the U.S. market, Dong-A ST is poised to make a significant impact.
Commitment to Patients and Healthcare
In addition to Imuldosa™, Dong-A ST underscores its dedication to developing innovative medicines that address unmet medical needs. With this latest FDA approval, they are further entrenching their role as a key player in the fight against autoimmune diseases through comprehensive solutions that improve patient outcomes.
Frequently Asked Questions
What is Imuldosa™?
Imuldosa™ is a biosimilar referencing Stelara®, used in treating autoimmune diseases.
Who approved Imuldosa™?
The U.S. Food and Drug Administration (FDA) approved Imuldosa™ for market use.
What diseases does Stelara® treat?
Stelara® addresses conditions like plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
When was the FDA approval announced?
The FDA approval for Imuldosa™ was announced on a recent date in October.
Which company markets Imuldosa™?
Imuldosa™ will be marketed through Intas Pharmaceuticals and its subsidiaries.
